The relationship between drug exposure and clinical outcomes of non-small cell lung cancer patients treated with gefitinib

Medical Oncology

Volumn 28, Issue 3, 2011, Pages 697-702

  Zhao, Yuan Yuan ^a   Li, Su ^a   Zhang, Yang ^a   Zhao, Hong Yun ^a   Liao, Hai ^a   Guo, Ying ^a   Shi, Yan Xia ^a   Jiang, Wei ^a   Xue, Cong ^a   Zhang, Li ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Clinical outcomes; Drug exposure; Gefitinib; Non small cell lung cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB;

ACNE; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DIARRHEA; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG EXPOSURE; FEMALE; GASTROINTESTINAL TOXICITY; GENE DELETION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MALE; OVERALL SURVIVAL; POINT MUTATION; PRIORITY JOURNAL; SKIN TOXICITY; TANDEM MASS SPECTROMETRY; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TANDEM MASS SPECTROMETRY; TREATMENT OUTCOME;

EID: 80052435929     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-010-9541-0     Document Type: Article

References (23)

1. TJ Lynch DW Bell R Sordella S Gurubhagavatula RA Okimoto BW Brannigan PL Harris SM Haserlat JG Supko FG Haluska, et al. 2004 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2129 2139 15118073 10.1056/NEJMoa040938 1:CAS:528:DC%2BD2cXktF2js7c%3D
2. JG Paez PA Janne JC Lee S Tracy H Greulich S Gabriel P Herman FJ Kaye N Lindeman TJ Boggon, et al. 2004 EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 1497 1500 15118125 10.1126/science.1099314 1:CAS:528:DC%2BD2cXksVGmsbs%3D
3. F Cappuzzo FR Hirsch E Rossi S Bartolini GL Ceresoli L Bemis J Haney S Witta K Danenberg I Domenichini, et al. 2005 Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer J Natl Cancer Inst 97 643 655 15870435 10.1093/jnci/dji112 1:CAS:528: DC%2BD2MXjvFymt70%3D
4. FR Hirsch M Varella-Garcia J McCoy H West AC Xavier P Gumerlock PA Bunn Jr WA Franklin J Crowley DR Gandara 2005 Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study J Clin Oncol 23 6838 6845 15998906 10.1200/JCO.2005.01.2823 1:CAS:528: DC%2BD2MXhtFCrsb3K
5. HC Swaisland RP Smith A Laight DJ Kerr M Ranson CH Wilder-Smith T Duvauchelle 2005 Single-dose clinical pharmacokinetic studies of gefitinib Clin Pharmacokinet 44 1165 1177 16231967 10.2165/00003088-200544110-00004 1:CAS:528:DC%2BD2MXhtlSgtbrJ
6. HK Jones LE Stafford HC Swaisland R Payne 2002 A sensitive assay for ZD1839 (Iressa) in human plasma by liquid-liquid extraction and high performance liquid chromatography with mass spectrometric detection: validation and use in Phase I clinical trials J Pharm Biomed Anal 29 221 228 12062681 10.1016/S0731-7085(02)00014-6 1:CAS:528:DC%2BD38Xktlynu7c%3D
7. SW Han TY Kim PG Hwang S Jeong J Kim IS Choi DY Oh JH Kim DW Kim DH Chung, et al. 2005 Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib J Clin Oncol 23 2493 2501 15710947 10.1200/JCO.2005.01.388 1:CAS:528: DC%2BD2MXjvVyktL0%3D
8. H Bai L Mao HS Wang J Zhao L Yang TT An X Wang CJ Duan NM Wu ZQ Guo, et al. 2009 Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer J Clin Oncol 27 2653 2659 19414683 10.1200/JCO.2008.17.3930 1:CAS:528:DC%2BD1MXnslWit7c%3D
9. J Albanell F Rojo S Averbuch A Feyereislova JM Mascaro R Herbst P LoRusso D Rischin S Sauleda J Gee, et al. 2002 Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition J Clin Oncol 20 110 124 11773160 10.1200/JCO.20.1.110 1:CAS:528:DC%2BD38XnsFersQ%3D%3D
10. J Baselga D Rischin M Ranson H Calvert E Raymond DG Kieback SB Kaye L Gianni A Harris T Bjork, et al. 2002 Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types J Clin Oncol 20 4292 4302 12409327 10.1200/JCO.2002.03.100 1:CAS:528:DC%2BD38Xpt1CjtLo%3D
11. M Fukuoka S Yano G Giaccone T Tamura K Nakagawa JY Douillard Y Nishiwaki J Vansteenkiste S Kudoh D Rischin, et al. 2003 Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected] J Clin Oncol 21 2237 2246 12748244 10.1200/JCO.2003.10.038 1:CAS:528:DC%2BD2cXpsVGqu7w%3D
12. G Giaccone RS Herbst C Manegold G Scagliotti R Rosell V Miller RB Natale JH Schiller J Von Pawel A Pluzanska, et al. 2004 Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1 J Clin Oncol 22 777 784 14990632 10.1200/JCO.2004.08.001 1:CAS:528:DC%2BD2cXpsVKjur4%3D
13. RS Herbst G Giaccone JH Schiller RB Natale V Miller C Manegold G Scagliotti R Rosell I Oliff JA Reeves, et al. 2004 Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2 J Clin Oncol 22 785 794 14990633 10.1200/JCO.2004.07.215 1:CAS:528:DC%2BD2cXpsVKjur0%3D
14. HC Swaisland MV Cantarini R Fuhr A Holt 2006 Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics Clin Pharmacokinet 45 633 644 16719544 10.2165/00003088-200645060-00006 1:CAS:528:DC%2BD28XmvVCmtrg%3D
15. J Li MO Karlsson J Brahmer A Spitz M Zhao M Hidalgo SD Baker 2006 CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors J Natl Cancer Inst 98 1714 1723 17148773 10.1093/jnci/djj466 1:CAS:528:DC%2BD28XhtlCru7nK
16. M Ranson S Wardell 2004 Gefitinib, a novel, orally administered agent for the treatment of cancer J Clin Pharm Ther 29 95 103 15068398 10.1111/j.1365-2710.2004.00543.x 1:CAS:528:DC%2BD2cXktFKqsbo%3D
17. J Li M Zhao P He M Hidalgo SD Baker 2007 Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes Clin Cancer Res 13 3731 3737 17575239 10.1158/1078-0432.CCR-07-0088 1:CAS:528:DC%2BD2sXmsFCqu7k%3D
18. JES Lu BL Lum M Hamilton A Rakhit J Gaudreault 2005 A population pharmacokinetic (PK) model for erlotinib (E), a small molecule inhibitor of the epidermal growth factor receptor (EGFR) [abstract 2032] JClin Oncol 23 143s 10.1200/JCO.2005.00.802
19. JF Lu SM Eppler J Wolf M Hamilton A Rakhit R Bruno BL Lum 2006 Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer Clin Pharmacol Ther 80 136 145 16890575 10.1016/j.clpt.2006.04.007 1:CAS:528:DC%2BD28XotFKhtr8%3D
20. M Hamilton JL Wolf J Rusk SE Beard GM Clark K Witt PJ Cagnoni 2006 Effects of smoking on the pharmacokinetics of erlotinib Clin Cancer Res 12 2166 2171 16609030 10.1158/1078-0432.CCR-05-2235 1:CAS:528:DC%2BD28XjtlChs7w%3D
21. M Hamilton JL Wolf D Zborowski 2005 Tarceva2 (erlotinib) exposure/effects (EE) analysis from a phase III study in advanced NSCLC: effect of smoking on the PK of erlotinib [abstract 6165] Proc Am Assoc Cancer Res 46 1451
22. W Pao V Miller M Zakowski J Doherty K Politi I Sarkaria B Singh R Heelan V Rusch L Fulton, et al. 2004 EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad Sci USA 101 13306 13311 15329413 10.1073/pnas.0405220101 1:CAS:528:DC%2BD2cXnvFems70%3D
23. H Shigematsu L Lin T Takahashi M Nomura M Suzuki II Wistuba KM Fong H Lee S Toyooka N Shimizu, et al. 2005 Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers J Natl Cancer Inst 97 339 346 15741570 10.1093/jnci/dji055 1:CAS:528: DC%2BD2MXitV2jsb4%3D